CDEK
← All drugs Report issue

aviptadil

Small moleculeexperimental

Clinical trial activity

7 trials · 25 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0

Earliest trial started Apr 30, 2020 (NCT04311697)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
Mol. weight
3326.84 g/mol
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05137795Phase 2/Phase 3 (Phase 3)Dec 15, 2021Cromos Pharma, LLC, Lugar Research Center, Tbilisi, Georgia, NeuroRx, Inc., NRx Pharmaceuticals
NCT04536350Phase 2May 18, 2021Cantonal Hosptal, Baselland, University of Basel
NCT04843761Phase 3Apr 20, 2021AIDS Clinical Trials Group, Cardiothoracic Surgical Trials Network, Department of Veteran Affairs, Gilead Sciences, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), Medical Research Council, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), NeuroRx, Inc., Prevention and Early Treatment of Acute Lung Injury (PETAL), University of Copenhagen, University of Minnesota, University of New South Wales, University of Utah
NCT04844580Phase 2Mar 10, 2021Centurion Pharma, Klinar CRO
NCT04360096Phase 2/Phase 3 (Phase 3)Jun 1, 2020NeuroRx, Inc.
NCT04311697Phase 2Apr 30, 2020Lavin Consulting, LLC, NeuroRx, Inc., Relief Therapeutics, Target Health Inc.
NCT04453839N/A—Cavendish Impact Foundation, NeuroRx, Inc.
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (25)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NeuroRx, Inc.For profit5432020
AIDS Clinical Trials GroupAcademic/Hospital1012021
Cantonal Hosptal, BasellandAcademic/Hospital1112021
Cardiothoracic Surgical Trials NetworkAcademic/Hospital1012021
Cavendish Impact FoundationAcademic/Hospital101—
Centurion PharmaFor profit1112021
Cromos Pharma, LLCFor profit1012021
Department of Veteran AffairsGovernment1012021
Gilead SciencesFor profit1012021
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)Academic/Hospital1012021
Klinar CROFor profit1012021
Lavin Consulting, LLCFor profit1012020
Lugar Research Center, Tbilisi, GeorgiaAcademic/Hospital1012021
Medical Research CouncilGovernment1012021
National Heart, Lung, and Blood Institute (NHLBI)Government1012021
National Institute of Allergy and Infectious Diseases (NIAID)Government1112021
NRx PharmaceuticalsFor profit1012021
Prevention and Early Treatment of Acute Lung Injury (PETAL)Academic/Hospital1012021
Relief TherapeuticsFor profit1012020
Target Health Inc.For profit1012020
25 organizations
Page 1 / 2